Revolution Medicines, Inc. Warrant Q1 FY2025 earnings call

Key Priorities and Progress - Revolution Medicines is committed to revolutionizing treatment for RAS-addicted cancers through innovative targeted medicines. - Progressed three clinical stage RAS(ON) inhibitors: daraxonrasib, elironrasib, and zoldonrasib. - In pancreatic cancer, advancing Phase 3 RASolute 302 trial and planning for additional Phase 3 studies in first-line metastatic and adjuvant settings. - For non-small cell lung cancer, outlined a strategy including segmentation of RAS mutant non-small cell lung cancer into G12C mutant and non-G12C RAS mutant groups, and plans for monotherapy and combination treatments with various inhibitors like daraxonrasib, zoldonrasib, elironrasib, and pembrolizumab. - Provided updates on clinical programs for daraxonrasib, zoldonrasib, and elironrasib in non-small cell lung cancer, including monotherapy activity and combination trial data. - Announced Anthony Mancini as Chief Global Commercialization Officer to oversee commercialization strategy.

In the first quarter of 2025, Revolution Medicines had $2.1 billion in cash and investments. R&D expenses were $205.7 million compared to $118 million in Q1 2024, primarily due to increases in clinical trial and manufacturing expenses for clinical stage programs. G&A expenses were $35 million compared to $22.8 million in Q1 2024, driven by increases in personnel and stock-based compensation. Net loss was $213.4 million compared to $116 million in Q1 2024. The company projects its cash can fund operations into the second half of 2027 based on current plans.

Revolution Medicines is reiterating its 2025 financial guidance. It continues to expect projected full year 2025 GAAP net loss to be between $840 million and $900 million, which includes estimated non-cash stock-based compensation expense of between $115 million and $130 million.

Q: Michael Schmidt asked about the first-line non-small cell lung cancer strategy, specifically confidence in the tolerability of the triplet of elironrasib, daraxonrasib, and pembrolizumab.

A: Wei Lin responded that they are optimistic given the profile seen so far, with no new safety signaling emerging and known safety signals like rash and QTc within expected ranges, and they will share more before initiating the Phase 3 trial after defining the final dose.

Q: Marc Frahm inquired about the average follow-up in cohorts and what's needed for Phase 3 intent for combinations.

A: Steve Kelsey stated that for the non-G12C program, it's more about operational execution, while for the G12C program, it's gated by optimizing the dose of the daraxonrasib and elironrasib combination. Response rate is a reasonable correlate of PFS in non-small cell lung cancer, and PFS isn't the sole driver for the G12C program decision.

Q: Eric Joseph asked about literature supporting response rate as a predictor for PFS outcomes and if they are continuing to enroll frontline lung cancer cohorts.

A: Mark Goldsmith mentioned references can be looked at offline for literature support, and there is ongoing dose optimization with continuing enrollment in frontline lung cancer cohorts.

Q: Jonathan Chang asked about the duration of clinical benefit of daraxonrasib versus mutant-selective inhibitors and its impact on development strategy.

A: Steve Kelsey explained that mechanism of escape from mutant-selective inhibitors is different from daraxonrasib, and the combination of RAS(ON) inhibitors covers putative mechanisms of escape, with the combination expected to have longer PFS, and they just need to wait for data to mature.

Q: Kelly Shi asked about resource allocation criteria for developments and cadence of initiating pivotal combination trials.

A: Mark Goldsmith stated that resource allocation considers clinical data, biological rationale, competitive landscape, and durable clinical benefit. They expect to begin rolling out first-line and combination studies in 2026 and are focused on delivering changes for patients across RAS mutations, tumor types, and lines of therapy.

Q: Ellie Merle asked about potential commercial strategy ex U.S., partnering philosophy, and details on pivotal combination trial designs and FDA interactions.

A: Mark Goldsmith said they can't provide specific timelines for FDA interactions, have had interest from global pharma companies for ex-U.S. commercialization, and are assessing options for serving patients internationally, but are not ready to make a strategic judgment on partnerships today.